ProMetic Life Sciences Inc. (TSE:PLI) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, November 13th.
Shares of ProMetic Life Sciences Inc. (TSE:PLI) opened at C$1.39 on Friday. ProMetic Life Sciences Inc. has a 52-week low of C$1.12 and a 52-week high of C$2.92.
PLI has been the topic of several analyst reports. National Bank Financial increased their target price on ProMetic Life Sciences from C$2.00 to C$2.50 in a research report on Wednesday, August 30th. TD Securities dropped their target price on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a research report on Wednesday, August 16th. Finally, Royal Bank Of Canada dropped their target price on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating on the stock in a research report on Wednesday, August 16th.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://sportsperspectives.com/2017/11/11/prometic-life-sciences-inc-pli-set-to-announce-quarterly-earnings-on-monday.html.
In other ProMetic Life Sciences news, insider Bruce Pritchard purchased 48,400 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was bought at an average price of C$1.30 per share, with a total value of C$62,920.00. Also, insider Jonathan Booth purchased 75,000 shares of the firm’s stock in a transaction dated Friday, October 6th. The stock was acquired at an average cost of C$1.21 per share, with a total value of C$90,750.00. In the last three months, insiders bought 184,150 shares of company stock valued at $231,429 and sold 388,397 shares valued at $507,577.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.